The role of inflammatory parameters in predicting disease recurrence in patients with stage IIA colon cancer with no high-risk features

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Epub 2018 Sep 12. DOI:10.3322/caac.21492
   Web of Science ®Google Scholar
• Vogel JD, Eskicioglu C, Weiser MR, et al. The American society of colon and rectal surgeons clinical practice guidelines for the treatment of colon cancer. Dis Colon Rectum. 2017;60(10):999.
   PubMed Web of Science ®Google Scholar
• Varghese A. Chemotherapy for Stage II Colon Cancer. Clin Colon Rectal Surg. 2015;28:256–261.
   PubMed Web of Science ®Google Scholar
• Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504–508.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899.
   PubMed Web of Science ®Google Scholar
• Ross DD, Stephen TM, James HP. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018. DOI:10.1038/s41416-018-0095-9
   Web of Science ®Google Scholar
• Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014;20:9872–9881.
   PubMed Web of Science ®Google Scholar
• Voronov E, Apte RN. IL-1 in colon inflammation, colon carcinogenesis and invasiveness of colon cancer. Cancer Microenviron. 2015;8:187–200.
   PubMed Web of Science ®Google Scholar
• Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872. Epub 2009 Jan 5.
   PubMed Web of Science ®Google Scholar
• O’Connell JB, Maggard MA, Ko CY, et al. Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420.
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797. Epub 2004 Apr 5.
   PubMed Web of Science ®Google Scholar
• Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51(5):503.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, et al. Colon cancer in France: evidence for improvement in management and survival. Gut. 2002;51(1):60.
   PubMed Web of Science ®Google Scholar
• Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines) colon cancer version 2. 2021 Jan 21 [cited 2021 May 6]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
   Google Scholar
• Ainhoa -C-C, Govind N, Sarah T Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. Available from: https://ascopubs.org/go/authors/open-accessforreuseterms
   Google Scholar
• Argilés G, Tabernero J, Labianca R. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020. DOI:10.1016/j.annonc.2020.06.022
   Google Scholar
• Sarraf KM, Belcher E, Raevsky E, et al. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425–428.
   PubMed Web of Science ®Google Scholar
• Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15–23.
   PubMed Web of Science ®Google Scholar
• Gomez D, Morris-Stiff G, Toogood GJ, et al. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;97(6):513–518.
   PubMed Web of Science ®Google Scholar
• Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008;32(8):1757–1762.
   PubMed Web of Science ®Google Scholar
• Rashtak S, Ruan X, Druliner BR, et al. Peripheral neutrophil to lymphocyte ratio improves prognostication in colon cancer. Clin Colorectal Cancer. 2017;16:115–123.e3.
   PubMed Web of Science ®Google Scholar
• George M, Marco G, Alan A, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014 Aug;260(2). DOI:10.1097/SLA.0000000000000216
   Web of Science ®Google Scholar
• Pei RD, Xin A, Rong XZ. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010;25:1427–1433.
   PubMed Web of Science ®Google Scholar
• Hsin-Y H, Jinn-S C, Chien YY. Effect of preoperative neutrophil–lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis. 2011;26:1059–1065.
   PubMed Web of Science ®Google Scholar
• Long Y, Wang T, Gao Q, et al. Prognostic signifcance of pretreatment elevated platelet count in patients with colorectal cancer: a meta-analysis. Oncotarget. 2016 Dec 6;7(49):81849–81861.
   PubMedGoogle Scholar
• Buergy D, Wenz F, Groden C, et al. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130:2747–2760.
   PubMed Web of Science ®Google Scholar
• Zhen YZ, Haı LL, Nıng N. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016;11:2241–2248.
   PubMed Web of Science ®Google Scholar
• Szkandera J, Martin P, Gudrun A. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg. 2014. DOI:10.1016/j.amjsurg.2013.10.030
   Web of Science ®Google Scholar
• Vayrynen JP, Tuomisto A, Klintrup K, et al. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer. 2013;109:1839–1847.
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–266.
   PubMed Web of Science ®Google Scholar
• Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435.
   PubMed Web of Science ®Google Scholar
• Masatsune S, Kiyoshi M, Hisashi N. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol. 2015 Sept 14;21(34):9966–9973. 2219-2840.
   PubMed Web of Science ®Google Scholar
• Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435–440.
   PubMed Web of Science ®Google Scholar
• Gruys E, Toussaint MJ, Niewold TA, et al. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005 Nov;6(11):1045–1056.
   PubMedGoogle Scholar
• Zhong JH, Huang DH, Chen ZY, et al. Prongostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:75381–75388.
   PubMedGoogle Scholar
• Ge X, Dai X, Ding C, et al. Early postoperative decrease of serum albumin predicts surgical outcome in patients undergoing colorectal resection. Dis Colon Rectum. 2017;60:326–334.
   PubMed Web of Science ®Google Scholar
• Katriina H, Shah E, Debbie AL. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007 Sept;61(9):824–833.
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. The creactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803–810.
   PubMed Web of Science ®Google Scholar
• Wei XL, Wang FH, Zhang DS, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer. 2015;15:350.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhan J, Hong S. Ratio of creactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep. 2015;5:10481.
   PubMed Web of Science ®Google Scholar
• Mitsuru I, Hitoshi N, Kazutoshi T. Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol. 2016. DOI:10.1245/s10434-015-4948-7
   Web of Science ®Google Scholar
• Fan W, Pei L, Feng-sen L. Prognostic role of C-reactive protein to albumin ratio in colorectal cancer. Medicine (Baltimore). 2019;98(29):e16064.
   PubMed Web of Science ®Google Scholar
• Hiroya M, Koji A, Qingjiang H, et al. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer. Int J Clin Oncol. 2020;25:1318–1326.
   PubMed Web of Science ®Google Scholar